Table 2.

Adjusted average healthcare costs for a standard patient for GP2017 and SB5 stratified by diagnosis.

Healthcare service	GP2017						SB5
	PsA		RA		AxSpA		PsA		RA		AxSpA
	Health costs (predicted)		Health costs (predicted)		Health costs (predicted)		Health costs (predicted)		Health costs (predicted)		Health costs (predicted)
	Before (€)	After (€)	Before (€)	After (€)	Before (€)	After (€)	Before (€)	After (€)	Before (€)	After (€)	Before (€)	After (€)
Hospital costs
Musculoskeletal system and the connective tissue	7.018	5.880	7.311	8.058	7.142	6.641	7.696	8.003	7.603	7.851	6.877	7.767
Other secondary sector treatment costs	824	614	313	310	520	1.070	446	500	442	677	640	476
Hospital total treatment costs	8.048	6.236	7.446	8.051	8.010	7.534	7.903	8.054	7.799	8.357	7.565	8.026
Primary sector
General practitioner	123	103	116	98	94	91	111	111	120	120	112	105
Specialist	70	124	81	56	58	108	56	81	40	40	81	54
Physiotherapist, chiropractor, and foot specialist	296	291	204	247	173	226	435	523	376	382	299	206
Other	52	48	47	42	31	80	58	43	40	41	56	51
Primary sector total costs	542	580	451	437	353	524	595	643	565	563	549	427
Prescription medication
Pain medication (DDD)	59	42	18	18	14	30	46	36	29	29	58	43
Not pain medication (DDD)	209	234	128	130	172	312	255	223	124	192	86	74
Prescription medication total costs (DDD)	273	275	148	151	186	335	311	274	149	220	142	110
Total healthcare costs	8.856	7.083	8.048	8.662	8.603	8.346	8.859	9.013	8.511	9.110	8.103	8.378

^aAdjusted average healthcare costs, given in euro (€), estimated for a “standard patient” defined as a 55-year-old female, with no previous comorbidities, with previous duration of originator adalimumab >6 years and not withdrawn biosimilar GP2017/SB5 within 180 days.

AxSpA, axial spondyloarthritis; DDD, defined daily dose; PsA, psoriatic arthritis; RA, rheumatoid arthritis.